In the adjuvant treatment of patients with early-stage NSCLC, PD-L1 expression of ≥50% on tumor cells (TCs) predicts an OS benefit from treatment with the PD-L1 inhibitor atezolizumab.8 The gene discussed is CD274; the disease is neoplasm.